Peter Wehrwein, Managing Editor

Associate director of healthcare and public health programs at the Digital Medicine Society (DiMe), a global nonprofit and professional home for digital medicine

Chief product and technology officer, Arcadia, a healthcare data company headquartered in Boston

Vice president of legal and compliance at Abarca Health, a pharmacy benefits manager and healthcare technology company.

Chief medical officer, complex care, AbsoluteCare, an integrated healthcare provider headquartered in Columbia, Maryland

Health Equity Officer at UCare, an independent, nonprofit health plan company with members in Minnesota and western Wisconsin

Director, specialty clinical solutions, Prime Therapeutics LLC, a pharmacy benefits manager in Eagan, Minnesota

Director, specialty pharmacy, Horizon Blue Cross Blue Shield of New Jersey

Vice president of implementation and sales, Longevity Health, a clinical services company and institutional special needs plan (ISNP) for nursing home residents

Executive director, specialty digital and patient innovation, CVS Health

Population health analyst on a dedicated health equity team, Optum Rx

Co-founder and CEO at Fabric Health, a public benefit corporation that conducts outreach about health benefits at laundromats

Director, formulary operations, Capital Rx, a pharmacy benefits manager and healthcare technology company

General counsel, 1upHealth, Inc., a healthcare data interoperability company in Boston.

The CDC has raised the recommded age at which people should get vaccinated to 75 and there are now three FDA-approved RSV vaccines

Health equity program director, Fallon Health, a not-for-profit health plan and provider of care headquartered in Worcester, Massachusetts.

But the Minnesota governor and Kamala Harris' running mate was endorsed by the United Auto Workers and other unions soon after this morning's announcement that he was her VP pick.

Humira and Sterlara are still the mainstays of spending, but Vizient that expenditures on drugs that treat genetic disorders will climb to $25 billion in 2026,

Nine of the 10 top specialty drugs by expenditure are biologics, according to the Pharmaceutical Strategies Group report on specialty drug spending.

Juan Michael Porter II, a prominent healthcare journalist and HIV advocate, spoke to MHE about keeping HIV/AIDS a priority and the dynamics of funding programs and pharmaceutical pricing

Phase 3 trials reported at the International AIDS Society meeting this week show no infections among those randomly assigned to twice-year injections of lenacapavir and no reason to be worried about safety,.

Results from the BEYOND trial show positive clinical outcomes and patient experiences.

Healthcare journalist, HIV advocate and educator Juan Michael Porter II discussed moderating the "Future of Science" session at the International AIDS Society's AIDS 2024 meeting in Munich, Germany, as well as addressing "founder's syndrome" in AIDS organizations and the inclusivity of the event.

The number of biologics approved as treatments for psoriasis has proliferated but the FDA has approved just four for use in children. Six biologics for pediatric psoriasis are in various stages of development.

Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.

The two-year study period might not have been long enough to capture tadalafil's effect, which could be positive for dry age-related macular degeneration (AMD) and negative for wet AMD.

Results of the American Society of Retina Specialists annual survey provide insight into opinions of its members and their current and future practice patterns.

Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.

Session on diabetic retinopathy includes results from trials of a variety of approaches to retinopathy.

Findings from an analysis of data from the pivotal PHOTON trial didn't show any increased risk of higher intraocular pressure building from injections of the high-dose, 8-mg version of Eylea.